Ultragenyx Pharmaceutical | RARE - Loan Capital

Stock Price
23.11
Daily Change
0.07 0.30%
Monthly
-6.13%
Yearly
-44.94%
Q1 Forecast
22.02

Ultragenyx Pharmaceutical reported $763.74M in Loan Capital for its fiscal quarter ending in September of 2025.





Loan Capital Change Date
Acadia Pharmaceuticals USD 0 0 Mar/2025
Agios Pharmaceuticals USD 1.06M 0 Sep/2022
Alnylam Pharmaceuticals USD 2.48B 1.44B Dec/2025
BioCryst Pharmaceuticals USD 194.37M 48.43M Sep/2025
BioMarin Pharmaceutical USD 597.18M 513K Dec/2025
Esperion Therapeutics USD 262.48M 235.95M Jun/2024
Immunic USD 0 0 Jun/2024
Insmed USD 540.96M 1.24M Dec/2025
Ionis Pharmaceuticals USD 1.9B 1.87B Dec/2025
Karyopharm Therapeutics USD -0.93 0.67 Dec/2024
Kyowa Hakko Kirin JPY 24.12B 5.27B Dec/2024
MacroGenics USD 70.26M 4K Sep/2025
Moderna USD 610M 584M Dec/2025
Neurocrine Biosciences USD 169.5M 500K Mar/2023
PTC Therapeutics USD 2.03B 193.22M Dec/2025
Puma Biotechnology USD 10.87M 222K Jun/2025
Regeneron Pharmaceuticals USD 2.71B 720.4M Dec/2025
Sarepta Therapeutics USD 828.97M 206.17M Dec/2025
Ultragenyx Pharmaceutical USD 763.74M 19.02M Sep/2025
Vertex Pharmaceuticals USD 111.4M 1.4M Mar/2025
Xoma USD 94.38M 7.82M Sep/2025